This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.
Another is Libtayo (cemiplimab), its latecomer checkpoint inhibitor which has however the first drug in the PD-1/PD-L1 class to be approved for cutaneous squamous cell carcinoma (CSCC), a
squamous cell carcinoma (CSCC). The Regeneron-partnered drug is the first drug in the checkpoint inhibitor class to get a green light in that type of skin cancer, and is also
It could also provide a leap forward for Libtayo, which was approved for cutaneous squamous cell carcinoma (CSCC) in the US in 2018 and in Europe earlier this year, but is
carcinoma (CSCC) in June. ... Regeneron books sales of Libtayo in the US, where it was approved for CSCC last year, and made $68m from the drug in the first half of the year.
It is too soon to gauge the take-up of Sanofi’s new cancer immunotherapy Libtayo (cemiplimab), which has just been approved for cutaneous squamous cell carcinoma (CSCC) in Europe after
CSCC is “physically and emotionally challenging, and there is a high unmet need for new treatments.”. ... NICE backing bodes well for other reimbursement decisions in Europe, but analysts don’t see the drug making a massive impact despite being on
More from news
Approximately 3 fully matching, plus 13 partially matching documents found.
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...